Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma

Toni K. Choueiri, Ulka Vaishampayan, Jonathan E. Rosenberg, Theodore Logan, Andrea L. Harzstark, Ronald M. Bukowski, Brian I. Rini, Sandy Srinivas, Mark N. Stein, Laurel M. Adams, Lone H. Ottesen, Kevin H. Laubscher, Laurie Sherman, David F. McDermott, Naomi B. Haas, Keith T. Flaherty, Robert Ross, Peter Eisenberg, Paul S. Meltzer, Maria J. MerinoDonald P. Bottaro, W. Marston Linehan, Ramaprasad Srinivasan

Research output: Contribution to journalArticle

244 Citations (Scopus)

Abstract

Purpose Foretinib is an oral multikinase inhibitor targeting MET, VEGF, RON, AXL, and TIE-2 receptors. Activating mutations or amplifications in MET have been described in patients with papillary renal cell carcinoma (PRCC). We aimed to evaluate the efficacy and safety of foretinib in patients with PRCC. Patients and Methods Patients were enrolled onto the study in two cohorts with different dosing schedules of foretinib: cohort A, 240 mg once per day on days 1 through 5 every 14 days (intermittent arm); cohort B, 80 mg daily (daily dosing arm). Patients were stratified on the basis of MET pathway activation (germline or somatic MET mutation, MET [7q31] amplification, or gain of chromosome 7). The primary end point was overall response rate (ORR). Results Overall, 74 patients were enrolled, with 37 in each dosing cohort. ORR by Response Evaluation Criteria in Solid Tumors (RECIST) 1.0 was 13.5%, median progression-free survival was 9.3 months, and median overall survival was not reached. The presence of a germline MET mutation was highly predictive of a response (five of 10 v five of 57 patients with and without germline MET mutations, respectively). The most frequent adverse events of any grade associated with foretinib were fatigue, hypertension, gastrointestinal toxicities, and nonfatal pulmonary emboli. Conclusion Foretinib demonstrated activity in patients with advanced PRCC with a manageable toxicity profile and a high response rate in patients with germline MET mutations.

Original languageEnglish
Pages (from-to)181-186
Number of pages6
JournalJournal of Clinical Oncology
Volume31
Issue number2
DOIs
StatePublished - Jan 10 2013

Fingerprint

Renal Cell Carcinoma
Biomarkers
Germ-Line Mutation
TIE-2 Receptor
GSK 1363089
Mutation
Chromosomes, Human, Pair 7
Embolism
Vascular Endothelial Growth Factor A
Disease-Free Survival
Fatigue
Appointments and Schedules
Hypertension
Safety
Lung
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Choueiri, T. K., Vaishampayan, U., Rosenberg, J. E., Logan, T., Harzstark, A. L., Bukowski, R. M., ... Srinivasan, R. (2013). Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. Journal of Clinical Oncology, 31(2), 181-186. https://doi.org/10.1200/JCO.2012.43.3383

Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. / Choueiri, Toni K.; Vaishampayan, Ulka; Rosenberg, Jonathan E.; Logan, Theodore; Harzstark, Andrea L.; Bukowski, Ronald M.; Rini, Brian I.; Srinivas, Sandy; Stein, Mark N.; Adams, Laurel M.; Ottesen, Lone H.; Laubscher, Kevin H.; Sherman, Laurie; McDermott, David F.; Haas, Naomi B.; Flaherty, Keith T.; Ross, Robert; Eisenberg, Peter; Meltzer, Paul S.; Merino, Maria J.; Bottaro, Donald P.; Linehan, W. Marston; Srinivasan, Ramaprasad.

In: Journal of Clinical Oncology, Vol. 31, No. 2, 10.01.2013, p. 181-186.

Research output: Contribution to journalArticle

Choueiri, TK, Vaishampayan, U, Rosenberg, JE, Logan, T, Harzstark, AL, Bukowski, RM, Rini, BI, Srinivas, S, Stein, MN, Adams, LM, Ottesen, LH, Laubscher, KH, Sherman, L, McDermott, DF, Haas, NB, Flaherty, KT, Ross, R, Eisenberg, P, Meltzer, PS, Merino, MJ, Bottaro, DP, Linehan, WM & Srinivasan, R 2013, 'Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma', Journal of Clinical Oncology, vol. 31, no. 2, pp. 181-186. https://doi.org/10.1200/JCO.2012.43.3383
Choueiri, Toni K. ; Vaishampayan, Ulka ; Rosenberg, Jonathan E. ; Logan, Theodore ; Harzstark, Andrea L. ; Bukowski, Ronald M. ; Rini, Brian I. ; Srinivas, Sandy ; Stein, Mark N. ; Adams, Laurel M. ; Ottesen, Lone H. ; Laubscher, Kevin H. ; Sherman, Laurie ; McDermott, David F. ; Haas, Naomi B. ; Flaherty, Keith T. ; Ross, Robert ; Eisenberg, Peter ; Meltzer, Paul S. ; Merino, Maria J. ; Bottaro, Donald P. ; Linehan, W. Marston ; Srinivasan, Ramaprasad. / Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. In: Journal of Clinical Oncology. 2013 ; Vol. 31, No. 2. pp. 181-186.
@article{3cfe1be817264b78840f6d7837237b62,
title = "Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma",
abstract = "Purpose Foretinib is an oral multikinase inhibitor targeting MET, VEGF, RON, AXL, and TIE-2 receptors. Activating mutations or amplifications in MET have been described in patients with papillary renal cell carcinoma (PRCC). We aimed to evaluate the efficacy and safety of foretinib in patients with PRCC. Patients and Methods Patients were enrolled onto the study in two cohorts with different dosing schedules of foretinib: cohort A, 240 mg once per day on days 1 through 5 every 14 days (intermittent arm); cohort B, 80 mg daily (daily dosing arm). Patients were stratified on the basis of MET pathway activation (germline or somatic MET mutation, MET [7q31] amplification, or gain of chromosome 7). The primary end point was overall response rate (ORR). Results Overall, 74 patients were enrolled, with 37 in each dosing cohort. ORR by Response Evaluation Criteria in Solid Tumors (RECIST) 1.0 was 13.5{\%}, median progression-free survival was 9.3 months, and median overall survival was not reached. The presence of a germline MET mutation was highly predictive of a response (five of 10 v five of 57 patients with and without germline MET mutations, respectively). The most frequent adverse events of any grade associated with foretinib were fatigue, hypertension, gastrointestinal toxicities, and nonfatal pulmonary emboli. Conclusion Foretinib demonstrated activity in patients with advanced PRCC with a manageable toxicity profile and a high response rate in patients with germline MET mutations.",
author = "Choueiri, {Toni K.} and Ulka Vaishampayan and Rosenberg, {Jonathan E.} and Theodore Logan and Harzstark, {Andrea L.} and Bukowski, {Ronald M.} and Rini, {Brian I.} and Sandy Srinivas and Stein, {Mark N.} and Adams, {Laurel M.} and Ottesen, {Lone H.} and Laubscher, {Kevin H.} and Laurie Sherman and McDermott, {David F.} and Haas, {Naomi B.} and Flaherty, {Keith T.} and Robert Ross and Peter Eisenberg and Meltzer, {Paul S.} and Merino, {Maria J.} and Bottaro, {Donald P.} and Linehan, {W. Marston} and Ramaprasad Srinivasan",
year = "2013",
month = "1",
day = "10",
doi = "10.1200/JCO.2012.43.3383",
language = "English",
volume = "31",
pages = "181--186",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "2",

}

TY - JOUR

T1 - Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma

AU - Choueiri, Toni K.

AU - Vaishampayan, Ulka

AU - Rosenberg, Jonathan E.

AU - Logan, Theodore

AU - Harzstark, Andrea L.

AU - Bukowski, Ronald M.

AU - Rini, Brian I.

AU - Srinivas, Sandy

AU - Stein, Mark N.

AU - Adams, Laurel M.

AU - Ottesen, Lone H.

AU - Laubscher, Kevin H.

AU - Sherman, Laurie

AU - McDermott, David F.

AU - Haas, Naomi B.

AU - Flaherty, Keith T.

AU - Ross, Robert

AU - Eisenberg, Peter

AU - Meltzer, Paul S.

AU - Merino, Maria J.

AU - Bottaro, Donald P.

AU - Linehan, W. Marston

AU - Srinivasan, Ramaprasad

PY - 2013/1/10

Y1 - 2013/1/10

N2 - Purpose Foretinib is an oral multikinase inhibitor targeting MET, VEGF, RON, AXL, and TIE-2 receptors. Activating mutations or amplifications in MET have been described in patients with papillary renal cell carcinoma (PRCC). We aimed to evaluate the efficacy and safety of foretinib in patients with PRCC. Patients and Methods Patients were enrolled onto the study in two cohorts with different dosing schedules of foretinib: cohort A, 240 mg once per day on days 1 through 5 every 14 days (intermittent arm); cohort B, 80 mg daily (daily dosing arm). Patients were stratified on the basis of MET pathway activation (germline or somatic MET mutation, MET [7q31] amplification, or gain of chromosome 7). The primary end point was overall response rate (ORR). Results Overall, 74 patients were enrolled, with 37 in each dosing cohort. ORR by Response Evaluation Criteria in Solid Tumors (RECIST) 1.0 was 13.5%, median progression-free survival was 9.3 months, and median overall survival was not reached. The presence of a germline MET mutation was highly predictive of a response (five of 10 v five of 57 patients with and without germline MET mutations, respectively). The most frequent adverse events of any grade associated with foretinib were fatigue, hypertension, gastrointestinal toxicities, and nonfatal pulmonary emboli. Conclusion Foretinib demonstrated activity in patients with advanced PRCC with a manageable toxicity profile and a high response rate in patients with germline MET mutations.

AB - Purpose Foretinib is an oral multikinase inhibitor targeting MET, VEGF, RON, AXL, and TIE-2 receptors. Activating mutations or amplifications in MET have been described in patients with papillary renal cell carcinoma (PRCC). We aimed to evaluate the efficacy and safety of foretinib in patients with PRCC. Patients and Methods Patients were enrolled onto the study in two cohorts with different dosing schedules of foretinib: cohort A, 240 mg once per day on days 1 through 5 every 14 days (intermittent arm); cohort B, 80 mg daily (daily dosing arm). Patients were stratified on the basis of MET pathway activation (germline or somatic MET mutation, MET [7q31] amplification, or gain of chromosome 7). The primary end point was overall response rate (ORR). Results Overall, 74 patients were enrolled, with 37 in each dosing cohort. ORR by Response Evaluation Criteria in Solid Tumors (RECIST) 1.0 was 13.5%, median progression-free survival was 9.3 months, and median overall survival was not reached. The presence of a germline MET mutation was highly predictive of a response (five of 10 v five of 57 patients with and without germline MET mutations, respectively). The most frequent adverse events of any grade associated with foretinib were fatigue, hypertension, gastrointestinal toxicities, and nonfatal pulmonary emboli. Conclusion Foretinib demonstrated activity in patients with advanced PRCC with a manageable toxicity profile and a high response rate in patients with germline MET mutations.

UR - http://www.scopus.com/inward/record.url?scp=84872548337&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872548337&partnerID=8YFLogxK

U2 - 10.1200/JCO.2012.43.3383

DO - 10.1200/JCO.2012.43.3383

M3 - Article

C2 - 23213094

AN - SCOPUS:84872548337

VL - 31

SP - 181

EP - 186

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 2

ER -